help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MYOU, S.
Right arrow Articles by HASHIMOTO, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MYOU, S.
Right arrow Articles by HASHIMOTO, T.

Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 40-44

Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, on Bronchial Hyperresponsiveness to Methacholine in Patients with Bronchial Asthma

SHIGEHARU MYOU, MASAKI FUJIMURA, YUMIE KAMIO, YOSHIHISA ISHIURA, KAZUYOSHI KURASHIMA, HIDEKI TACHIBANA, TATSUKI HIROSE, and TAKUMA HASHIMOTO

Third Department of Internal Medicine and Department of Laboratory Medicine, Kanazawa University School of Medicine, Kanazawa, Japan; and Central Laboratory, Kanazawa University Hospital, Kanazawa, Japan

It is unclear whether angiotensin II receptors are involved in bronchial hyperresponsiveness in asthmatic patients. We examined the effect of losartan, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in eight patients with stable asthma. Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1) and a 35% fall in standardized partial expiratory flow at 40% of FVC (PC35-PEF40), was measured on two occasions 2 wk apart. Losartan (50 mg once a day) or a placebo was orally administered for 1 wk before methacholine provocation test in a double-blind, randomized, crossover fashion. Although the PC20-FEV1 values after placebo (2.037 [geometric standard error of the mean, GSEM = 0.210] mg/ml) and losartan (2.098 [GSEM, 0.239] mg/ml) were identical (p = 0.840), the geometric mean PC35-PEF40 values significantly (p = 0.034) increased from 0.258 (GSEM, 0.156) mg/ml with placebo to 0.456 (GSEM, 0.186) mg/ml with losartan. We conclude that AT1 receptors are involved in bronchial hyperresponsiveness in asthmatic patients. This is the first report demonstrating the involvement of AT1 receptors in bronchial asthma.




This article has been cited by other articles:


Home page
 ChestHome page
M. Cazzola, P. Noschese, G. D'Amato, and M. G. Matera
The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction
Chest, January 1, 2002; 121(1): 230 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]

Home page
 CirculationHome page
H. Tanaka, S. Teramoto, K. Oashi, T. Saikai, S. Tanaka, K. Suzuki, M. Hashimoto, and S. Abe
Effects of Candesartan on Cough and Bronchial Hyperresponsiveness in Mildly to Moderately Hypertensive Patients With Symptomatic Asthma
Circulation, July 17, 2001; 104(3): 281 - 285.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society